SEARCH

SEARCH BY CITATION

References

  • 1
    Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:23682374.
  • 2
    McKay DW, Myers MG, Bolli P, Chockalingam A. Masked hypertension: a common but insidious presentation of hypertension. Can J Cardiol. 2006;22:617620.
  • 3
    Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens. 1995;13(12 Pt 1):13771390.
  • 4
    Waeber B. What is behind masked hypertension? Rev Med Suisse. 2005;1:20892091.
  • 5
    Pickering TG. Effects of stress and behavioral interventions in hypertension: what is masked hypertension? J Clin Hypertens (Greenwich). 2003;5:171174.
  • 6
    Palatini P. Masked hypertension: how can the condition be detected? Blood Press Monit. 2004;9:297.
  • 7
    Mancia G, Carugo S, Grassi G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Hypertension. 2002;39:744749.
  • 8
    Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population PAMELA Study. Circulation. 2001;104:13851392.
  • 9
    Tomiyama M, Horio T, Kamide K, et al. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension. J Hum Hypertens. 2007;21:212219.
  • 10
    Hara A, Ohkubo T, Kikuya M, et al. Detection of carotid atherosclerosis in individuals with masked hypertension and white-coat hypertension by self-measured blood pressure at home: the Ohasama Study. J Hypertens. 2007;25:321327.
  • 11
    Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:14221428.
  • 12
    Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846853.
  • 13
    Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens. 2006;19:880886.
  • 14
    Kato T, Horio T, Tomiyama M, et al. Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients. Nephrol Dial Transplant. 2007;22:911916.
  • 15
    Bełtowski J. Apelin and visfatin: unique “beneficial” adipokines upregulated in obesity? Med Sci Monit. 2006;12:RA112RA119.
  • 16
    Time Magazine. 1944-04-10. http://www.time.com/time/magazine/article/0,9171,796530,00.html. Accessed May 20, 2009.
  • 17
    Becker GJ, Hewitson TD. “Relaxin and renal fibrosis.” Kidney Int. March 2001;59:11841185.
  • 18
    Wilkinson TN, Speed TP, Tregear GW, Bathgate RA. “Evolution of the relaxin-like peptide family.” BMC Evol Biol. February 2005;5:14.
  • 19
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 20
    Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 21
    Papadopoulos DP, Makris TK. “Masked hypertension- definition-impact-outcomes a critical review.” J Clin Hypertens (Greenwich). 2007;9:956963.
  • 22
    Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens. 2012;25:664671.
  • 23
    Sharman JE, Hare JL, Thomas S, et al. Association of masked hypertension and left ventricular remodeling with the hypertensive response to exercise. Am J Hypertens. 2011;24:898903.
  • 24
    Hänninen MR, Niiranen TJ, Puukka PJ, et al. Determinants of masked hypertension in the general population: the Finn-Home study. J Hypertens. 2011;29:18801888.
  • 25
    Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem. 2007;5:110.
  • 26
    Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:3441.
  • 27
    Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxidedependent mechanism. Regul Pept. 2001;99:8792.
  • 28
    Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279:2627426279.
  • 29
    Falcão-Pires I, Castro-Chaves P, Miranda-Silva D, et al. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today. 2012;17:880889.
  • 30
    Sonmez A, Celebi G, Erdem G, et al. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32:179183.
  • 31
    Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens. 2011;29:971979.
  • 32
    Sherwood O. Relaxin's physiological roles and other diverse actions. Endocrinol Rev. 2004;25:205234.
  • 33
    Conrad KP, Novak J. The emerging role of relaxin in renal and cardiovascular function. Am J Physiol. 2004;287:R250R261.
  • 34
    Bani D, Bigazzi M. Relaxin as a cardiovascular drug: a promise kept. Curr Drug Saf. 2011;6:324328.
  • 35
    Tanaka M. Relaxin-3/insulin-like peptide 7, a neuropeptide involved in the stress response and food intake. FEBS J. 2010;277:49904997.
  • 36
    Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321329.
  • 37
    Xu Q, Chakravorty A, Bathgate RA, et al. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension. May 2010;55:12601266.
  • 38
    Gedikli O, Yilmaz H, Kiris A, et al. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Press. 2009;18:6873.